Novartis Venture Funds

About The Fund

The Novartis Venture Fund (NVF) is a venture capital fund focused on nurturing and investing in innovative life science companies to foster innovation, drive significant patient benefit, and generate superior returns. Located at 196 Broadway, Cambridge, Massachusetts, NVF manages over USD 2.5 billion in committed capital and supports more than 40 portfolio companies across North America and Europe. Their investment thesis revolves around growing and developing novel therapeutics and platforms that address unmet patient needs across the healthcare spectrum around the world. NVF takes a hands-on approach to its investments, which span various growth and development stages, including biotechnology and biopharmaceuticals, IT & TMT, HealthTech & Fitness, Medical Devices & Hospital Services, and Pharmaceuticals & Medicine. The fund's expertise in Equity and specialities in Expansion and Later Stage ventures makes it a critical player in advancing scientific innovation. With a mix of early-stage startups and later-stage companies, NVF collaborates closely with board members and management to deliver real clinical impact. Their investment team, split between Basel, Switzerland, and their headquarters in Cambridge, Massachusetts, possesses proven expertise and talent in drug development, with strong backgrounds in life science and business growth. The Novartis Venture Fund is committed to investing their expertise and experience in the future health of patients worldwide, with a track record of success in IPOs, Mergers & Acquisitions, and scientific breakthroughs.